Recon Strategy
Contact

Insights

Fifteen+ years of
Healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

Sector
All
NEJM opinion

Why the Best AI Won’t Win in Healthcare

  • Biopharma , 
  • Payers , 
  • Providers , 
  • Medtech , 
  • Digital
As advanced AI becomes widely accessible, healthcare companies can no longer rely on superior technology alone for lasting advantage. Instead, they need a coherent AI strategy built around five interconnected choices. Harvard Business Review article.

Read more

Stylized representation of digital health

Keys to harnessing the value of digital biomarkers in clinical trials

  • Biopharma , 
  • Medtech , 
  • Digital , 
Digital biomarkers are no longer just a pipe dream—they are here, and their use is potentially at an inflection point. However, successful implementation requires more than enthusiasm; it demands thoughtful strategies tailored to each clinical innovation, therapeutic area, and digital tool.

Read more

A Kaplan-Meier view of oncology development

  • Biopharma , 
  • Digital , 
We refresh a prior analysis of two cohorts of oncology development pro…

Read more

Multi-Cancer Early Detection tests – Will they become part of regular clinical care?

PDF here Summary The idea of a single blood-test to detect many cancer…

Read more

The road ahead for genomic testing

  • Biopharma , 
  • Payers , 
  • Medtech , 
New molecular diagnostics, especially tests based on next-generation s…

Read more

AI in healthcare III: COVID-19 applications and implications

  • Biopharma , 
  • Payers , 
  • Providers , 
  • Medtech , 
  • Digital , 
COVID-19 has accelerated the adoption of AI in healthcare. AI based to…

Read more

Strategy in the Time of Covid

  • Biopharma , 
  • Payers , 
  • Providers , 
  • Medtech , 
  • Digital , 
Preamble A recent post from Recon Strategy outlined the longer-term st…

Read more

The day after: Implications for hospitals, payers, biotech and more…

  • Biopharma , 
  • Payers , 
  • Providers , 
  • Medtech , 
  • Digital
Even as our priority today is dealing with the Covid crisis, healthcar…

Read more

New class of therapeutics calls for new regulations: thoughts on the FDA’s new process for regulating digiceuticals

  • Medtech , 
  • Digital
Interest and investment in digital health has increased rapidly in rec…

Read more

Attacking an oligopoly by integrating downstream services: Can Livongo’s closed loop get traction vs. the big glucometer incumbents?

  • Medtech , 
  • Digital , 
Summary Livongo is marrying a cellular-enabled glucometer and a data …

Read more

The future of cancer care: A bird’s-eye view

  • Biopharma , 
  • Medtech
The recent World Medical Innovation Forum on Cancer convened by Partne…

Read more

When is a patient not a patient? More often than you think

  • Medtech , 
  • Digital , 
I have been conducting an informal test for the past year and a half. …

Read more

Boiling the Ocean…or not

  • Payers , 
  • Providers , 
  • Digital , 
We've all heard the term, "Boiling the Ocean" to refer to an approach …

Read more